Hospital stocks rally while drugmakers brace for scrutiny. Here’s what the Democratic wave means for healthcare.

The Democratic victory in the midterm elections is expected to have a positive impact on hospital stocks, as the party's healthcare agenda is seen as favorable to hospital operators. With Democrats likely to push for increased funding for healthcare programs and a potential expansion of Medicaid, hospitals could see an increase in patient volumes and reimbursements. This is a welcome development for hospital stocks, which have faced pressure in recent years due to reimbursement cuts and regulatory uncertainty.

The rally in hospital stocks is also driven by the expectation that a Democratic-controlled House of Representatives will be less likely to implement significant changes to the Affordable Care Act, also known as Obamacare. The ACA has been a boon to hospitals, as it has increased the number of insured patients and provided additional funding for safety-net hospitals. With a Democratic majority, hospitals are likely to face a more stable regulatory environment, which could help to boost their financial performance.

Drugmakers, on the other hand, are bracing for scrutiny, as Democrats have vowed to take a tougher stance on pharmaceutical prices. With a number of high-profile drug pricing investigations already underway, drugmakers could face increased pressure to justify their pricing practices. Trade-watchers should keep an eye on any developments related to drug pricing legislation or investigations, as these could have a significant impact on the financial performance of drugmakers and the overall healthcare sector.

Originally reported by marketwatch.com. Trade-News adds analysis for finance & markets readers.